Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Abstract

BackgroundPhase III trials demonstrated effectiveness of tofacitinib, an oral Janus kinase inhibitor, to induce and maintain remission in patients with moderate-to-severe active ulcerative colitis (UC). AimsWe report the real-world effectiveness and safety of tofacitinib in patients with UC in France. MethodsFrom February 2017 to December 2018, we performed a national French cohort study, which included all consecutive patients with an active UC refractory to anti-TNF and vedolizumab, who received tofacitinib. Outcomes were survival without colectomy, survival without tofacitinib discontinuation and steroid-free clinical remission at weeks 14, 24 and 48. ResultsThirty-eight patients were included, with a median follow-up of 41.5 (18.5–56.8) weeks. Survival without colectomy was 77% [95% confidence interval (95%CI): 59.3–87.9] at week 24 and 70% (95%CI: 50.9–82.8) at week 48. Survival without treatment discontinuation was 70% (95%CI: 52.6–82.3) at week 24. Steroid-free clinical remission was observed in 13 (34%) patients at week 48. Adverse events occurred in 14 (37%) patients, including 6 severe adverse events and three herpes zoster infections. ConclusionIn a highly refractory UC population, one third of patients treated with tofacitinib achieved steroid-free clinical remission at week 14 and 70% of patients avoided colectomy at one year, with an acceptable safety profile. These data confirm tofacitinib effectiveness in UC, especially after multiple biologic failures.